To study the effect of the drug Sacubutril-Valsartan on diastolic function in heart failure patients
Not Applicable
- Conditions
- Health Condition 1: I501- Left ventricular failure, unspecifiedHealth Condition 2: I30-I52- Other forms of heart disease
- Registration Number
- CTRI/2020/04/024445
- Lead Sponsor
- Kasturba Medical College Manipal Academy of Higher Education Manipal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age greater than 18 years
2. Able to provide written and informed consent
3. Left ventricular ejection fraction less than 40%
4. NYHA II- IV symptoms
5. Newly diagnosed heart failure with reduced ejection fraction
6. Chronic heart failure with reduced ejection fraction patients who are on optimal medical treatment but not started on ARNI Sacubutril- Valsartan
Exclusion Criteria
1. Recent coronary revascularization within 3 months
2. Hypotension
3. Renal dysfunction
4. Valvular heart disease other than mitral regurgitation
5. Recent cardiac resynchronization therapy device implantation within 3 months
6. Any contraindication for ARNI Sacubutril -Valsartan
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diastolic strain rate at the baseline and at 3 months after starting Sacubutril - Valsartan will be compared and will also be compared with the control groupTimepoint: 1. At baseline before starting Sacubutril- Valsartan <br/ ><br>2. At 3 months after starting the treatment <br/ ><br>
- Secondary Outcome Measures
Name Time Method Global longitudinal strain, E/E, LV Ejection fraction at baseline before starting the drug and after starting the drug , will be compared and will also be compared with the control groupTimepoint: 1. At baseline before starting Sacubutril- Valsartan <br/ ><br>2. At 3 months after starting the treatment <br/ ><br>